InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,430.40
(
0.14%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.70
(
-0.11%
)
Bitcoin
64,885.11
(
-0.39%
)
Post# of 252255
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: ghmm post# 127207

Thursday, 09/29/2011 3:33:11 PM

Thursday, September 29, 2011 3:33:11 PM

Post# of 252255
BMRN

On PEG-PAL

The program has some questions in my mind

Yeah, I can see quite a few: dose/dosing, formulations, potency (needs to be more effective than Kuvan and needs to maintain it over time), rate of allergic reactions. I've looked for new data from PEG-PAL's phase II trial but couldn't find in their web. Perhaps they've updated at some recent conference?

GALNS is still the key

And I feel more confidant with GALNS given the 2 years data from phase 1/2 extension trial:

http://phx.corporate-ir.net/phoenix.zhtml?c=106657&p=irol-newsArticle&ID=1590497&highlight=
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up